ADMA Biologics, Inc.
ADMA
$17.10
-$0.20-1.16%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 474.17M | 459.38M | 426.45M | 382.81M | 330.25M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 474.17M | 459.38M | 426.45M | 382.81M | 330.25M |
| Cost of Revenue | 222.86M | 217.84M | 206.90M | 193.40M | 175.85M |
| Gross Profit | 251.32M | 241.54M | 219.55M | 189.41M | 154.40M |
| SG&A Expenses | 92.91M | 87.09M | 78.37M | 69.30M | 64.91M |
| Depreciation & Amortization | 110.00K | 220.00K | 388.00K | 550.00K | 701.00K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 318.53M | 307.34M | 287.47M | 265.12M | 243.51M |
| Operating Income | 155.64M | 152.04M | 138.98M | 117.69M | 86.74M |
| Income Before Tax | 145.01M | 140.76M | 125.71M | 73.36M | 39.17M |
| Income Tax Expenses | -63.92M | -66.01M | -71.96M | 5.22M | 4.38M |
| Earnings from Continuing Operations | 208.93 | 206.77 | 197.67 | 68.13 | 34.79 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 208.93M | 206.77M | 197.67M | 68.13M | 34.79M |
| EBIT | 155.64M | 152.04M | 138.98M | 117.69M | 86.74M |
| EBITDA | 163.55M | 159.94M | 147.03M | 125.90M | 95.10M |
| EPS Basic | 0.88 | 0.88 | 0.84 | 0.29 | 0.15 |
| Normalized Basic EPS | 0.39 | 0.38 | 0.34 | 0.28 | 0.19 |
| EPS Diluted | 0.86 | 0.85 | 0.82 | 0.28 | 0.14 |
| Normalized Diluted EPS | 0.37 | 0.36 | 0.33 | 0.27 | 0.18 |
| Average Basic Shares Outstanding | 950.27M | 941.20M | 932.30M | 921.83M | 912.54M |
| Average Diluted Shares Outstanding | 983.99M | 977.55M | 969.29M | 949.35M | 938.31M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |